What happenedŠta se dogodilo
The US Food and Drug Administration convened its Pharmacy Compounding Advisory Committee on 23–24 July 2026. On the first day, the committee discussed BPC-157-, KPV-, TB-500- and MOTS-c-related bulk drug substances for possible inclusion on the section 503A Bulks List. Emideltide (DSIP), Semax and Epitalon-related substances were discussed on the second day.Američka Uprava za hranu i lekove sazvala je Savetodavni odbor za izradu lekova 23–24. jula 2026. Prvog dana odbor je razmatrao supstance povezane sa BPC-157, KPV, TB-500 i MOTS-c radi mogućeg uključivanja na 503A listu aktivnih supstanci. Drugog dana razmatrane su supstance povezane sa Emideltidom (DSIP), Semaxom i Epitalonom.
FDA’s meeting page identifies the proposed uses the agency evaluated and provides briefing documents, presentations and the public docket. It also states that advisory committees make non-binding recommendations: FDA considers their advice but is not legally bound by it.Stranica FDA o sastanku navodi predložene namene koje je agencija procenjivala i objavljuje informativna dokumenta, prezentacije i javni predmet. Takođe navodi da savetodavni odbori daju neobavezujuće preporuke: FDA razmatra njihov savet, ali njime nije pravno vezana.
Why it mattersZašto je važno
The 503A Bulks List concerns conditions under which certain bulk drug substances may be used in pharmacy compounding. Consideration for that list is a regulatory event worth tracking, but it is not a finding that a substance is safe or effective, not approval of a finished drug, and not authorization of material sold outside the applicable legal framework.503A lista aktivnih supstanci odnosi se na uslove pod kojima se određene aktivne supstance mogu koristiti u apotekarskoj izradi lekova. Razmatranje za tu listu je regulatorni događaj vredan praćenja, ali nije zaključak da je supstanca bezbedna ili efikasna, nije odobrenje gotovog leka i nije dozvola za materijal koji se prodaje van primenljivog pravnog okvira.
What remains unresolvedŠta ostaje nerešeno
AEVANOVA will treat any later FDA rulemaking or agency action as a separate update. Until an official action is published, the meeting record should not be shortened to “FDA approved” or “FDA cleared.”AEVANOVA će svako kasnije pravilo ili postupanje FDA tretirati kao zasebno ažuriranje. Dok zvanična odluka ne bude objavljena, zapis o sastanku ne treba skraćivati na „FDA odobrila“ ili „FDA prihvatila“.